1. Home
  2. IDYA vs TMDX Comparison

IDYA vs TMDX Comparison

Compare IDYA & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • TMDX
  • Stock Information
  • Founded
  • IDYA 2015
  • TMDX 1998
  • Country
  • IDYA United States
  • TMDX United States
  • Employees
  • IDYA N/A
  • TMDX N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • IDYA Health Care
  • TMDX Health Care
  • Exchange
  • IDYA Nasdaq
  • TMDX Nasdaq
  • Market Cap
  • IDYA 2.0B
  • TMDX 2.4B
  • IPO Year
  • IDYA 2019
  • TMDX 2019
  • Fundamental
  • Price
  • IDYA $21.85
  • TMDX $71.95
  • Analyst Decision
  • IDYA Strong Buy
  • TMDX Buy
  • Analyst Count
  • IDYA 13
  • TMDX 11
  • Target Price
  • IDYA $53.67
  • TMDX $116.10
  • AVG Volume (30 Days)
  • IDYA 972.2K
  • TMDX 1.3M
  • Earning Date
  • IDYA 02-13-2025
  • TMDX 02-27-2025
  • Dividend Yield
  • IDYA N/A
  • TMDX N/A
  • EPS Growth
  • IDYA N/A
  • TMDX N/A
  • EPS
  • IDYA N/A
  • TMDX 0.94
  • Revenue
  • IDYA $7,000,000.00
  • TMDX $401,090,000.00
  • Revenue This Year
  • IDYA $111.81
  • TMDX $81.61
  • Revenue Next Year
  • IDYA $240.55
  • TMDX $22.52
  • P/E Ratio
  • IDYA N/A
  • TMDX $76.78
  • Revenue Growth
  • IDYA N/A
  • TMDX 109.09
  • 52 Week Low
  • IDYA $19.96
  • TMDX $55.00
  • 52 Week High
  • IDYA $47.72
  • TMDX $177.37
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 43.52
  • TMDX 52.52
  • Support Level
  • IDYA $19.96
  • TMDX $66.81
  • Resistance Level
  • IDYA $21.65
  • TMDX $80.00
  • Average True Range (ATR)
  • IDYA 1.09
  • TMDX 4.14
  • MACD
  • IDYA -0.07
  • TMDX 0.57
  • Stochastic Oscillator
  • IDYA 33.57
  • TMDX 48.74

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: